Showing results (541-550 of 607) with videos related to
Sort By:
Pageof 61
Pharmacoeconomics - Open|July 28, 2022
Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 TrialF Felizzi, Aino Launonen, P-O ThuressonPharmacoeconomics - Open|July 13, 2022
Using Health Economics to Inform Immunization Policy Across All Levels of GovernmentEllen Rafferty, Laura Reifferscheid, Ali Assi, et al.Pharmacoeconomics - Open|January 26, 2023
Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom PerspectiveFrançois-Xavier Chalet, Teodora Bujaroska, Evi Germeni, et al.Pharmacoeconomics - Open|March 17, 2023
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in ItalyPaolo Angelo Cortesi, Carla Fornari, Paolo Gisondi, et al.Pharmacoeconomics - Open|September 1, 2021
Budget Impact of the Vest™ High Frequency Chest Wall Oscillation System for Managing Airway Clearance in Patients with Complex Neurological Disorders: A US Healthcare Payers' Perspective AnalysisAmir Ansaripour, Kari Roehrich, Atefeh Mashayekhi, et al.Pharmacoeconomics - Open|March 11, 2023
Cost Analysis of a Transition Care Bundle Compared with Usual Care for COPD Patients Being Discharged from Hospital: Evaluation of a Randomized Controlled TrialCharles Yan, Jeff Round, Ilke Akpinar, et al.Pharmacoeconomics - Open|February 3, 2023
Cost-Utility Analysis of the Caresyntax Platform to Identify Patients at Risk of Surgical Site Infection Undergoing Colorectal SurgeryEoin Moloney, Atefeh Mashayekhi, Mehdi Javanbakht, et al.Pharmacoeconomics - Open|February 9, 2023
The Burden of Caring for Individuals with Tuberous Sclerosis Complex (TSC) Who Experience Epileptic Seizures: A Descriptive UK SurveyHanna Skrobanski, Kishan Vyas, Sally Bowditch, et al.Pharmacoeconomics - Open|February 9, 2023
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in SwitzerlandEsra Çakar, César Oniangue-Ndza, Ralph P Schneider, et al.Pharmacoeconomics - Open|February 11, 2023
A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of AmericaAaron Winn, Anirban Basu, Scott D RamseyPageof 61